BRCA1 at the crossroad of multiple cellular pathways: Approaches for therapeutic interventions

Molecular Cancer Therapeutics

Volumn 5, Issue 6, 2006, Pages 1396-1404

  Yarden, Ronit I ^a   Papa, Moshe Z ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE;

APOPTOSIS; BIOCHEMISTRY; BREAST CANCER; CANCER CELL; CANCER INVASION; CELL CYCLE REGULATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL; DNA REPAIR; GENE MUTATION; GENOMIC INSTABILITY; GERM LINE; HEREDITY; HETEROZYGOTE; HUMAN; IONIZING RADIATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; UBIQUITINATION;

ANIMALS; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; SIGNAL TRANSDUCTION;

EID: 33746050405     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0471     Document Type: Review

References (78)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266: 66-71.
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2 [see comments]. Nature 1995; 378:789-92. Published erratum appears in Nature 1996 Feb 22; 379:749.
3. Cornelis RS, Neuhausen SL, Johansson O, et al. High allele loss rates at 17q12-21 in breast and ovarian tumors from BRCA1-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer 1995; 13:203-10.
4. Collins N, McManus R, Wooster R, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995;10:1673-5.
5. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews [see comments]. N Engl J Med 1997;336:1401-8.
6. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
7. Catteau A, Morris JR. BRCA1 methylation: a significant role in tumour development? Semin Cancer Biol 2002;12:359-71.
8. Hilton JL GJ, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94:1396-406.
9. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A 1999;96:11364-9.
10. Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J 1997;11:68-76.
11. Manke IA, Lowery DM, Nguyen A, Yaffe MB. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 2003;302:636-9.
12. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phospho-protein binding domain. Science 2003;302:639-42.
13. Parvin JD. Overview of history and progress in BRCA1 research: the first BRCA1 decade. Cancer Biol Ther 2004;3:505-8.
14. Deng CX. Tumor formation in Brca1 conditional mutant mice. Environ Mol Mutagen 2002;39:171-7.
15. Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat Genet 1997;16:298-302.
16. Xu X, Qiao W, Linke SP, et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 200 1;28:266-71.
17. Xu X, Wagner KU, Larson D, et al. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation [see comments]. Nat Genet 1999;22:37-43.
18. Phillips KA, Nichol K, Ozcelik H, et al. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst 1999;91:469-73.
19. Ramus SJ, Bobrow LG, Pharoah PD, et al. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer 1999;25:91-6.
20. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005;23:1656-63.
21. Bachelier R, Xu X, Li C, et al. Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice. Oncol Rep 2005; 14: 1117-20.
22. Jones LP, Li M, Halama ED, et al. Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. Oncogene 2005;24:3554-62.
23. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82.
24. Chen J. Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage. Cancer Res 2000;60:5037-9.
25. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks [see comments]. Science 1999;286:1162-6.
26. Tibbetts RS, Cortez D, Brumbaugh KM, et al. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress [in process citation]. Genes Dev 2000; 14:2989-3002.
27. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. hCds1 -mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000;404:201-4.
28. Chiba N, Parvin JD. Redistribution of BRCA1 among four different protein complexes following replication blockage. J Biol Chem 2001;276: 38549-54.
29. Xu B, O'Donnell AH, Kim ST, Kastan MB. Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res 2002;62:4588-91.
30. Xu B, Kim S, Kastan MB. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001;21: 3445-50.
31. Martin SA, Ouchi T. BRCA1 phosphorylation regulates caspase-3 activation in UV-induced apoptosis. Cancer Res 2005;65:10657-62.
32. 2-M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 2002;30:285-9.
33. Gilbert CS, Green CM, Lowndes NF. Budding yeast Rad9 is an ATP-dependent Rad53 activating machine. Mol Cell 2001;8:129-36.
34. Saka Y, Esashi F, Matsusaka T, Mochida S, Yanagida M. Damage and replication checkpoint control in fission yeast is ensured by interactions of Crb2, a protein with BRCT motif, with Cut5 and Chk1. Genes Dev 1997; 11:3387-400.
35. Joughin BA, Tidor B, Yaffe MB. A computational method for the analysis and prediction of protein: phosphopeptide-binding sites. Protein Sci 2005; 14:131-9.
36. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88:265-75.
37. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 2001;61:4842-50.
38. Snouwaert JN, Gowen LC, Latour AM, et al. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. Oncogene 1999;18: 7900-7.
39. 2-M Cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 1999; 3:389-95.
40. Tomlinson GE, Chen TT, Stastny VA, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 1998;58:3237-42.
41. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000;14:927-39.
42. Zhong QCC, Li S, Chen Y, et al. Association of BRCA1 with the hRad50-11-p95 complex and the DNA damage response. Science 1999; 285:747-50.
43. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10: 886-95.
44. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004;96:1659-68.
45. Pierce L. Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas. Semin Radiat Oncol 2002; 12: 352-61.
46. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21.
47. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
48. Harkin DP, Bean JM, Miklos D, et al. Induction of GADD45 and JNK/ SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999;97:575-86.
49. Li S, Ting NS, Zheng L, et al. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature 2000;406: 210-5.
50. Zhang H, Somasundaram K, Peng Y, et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 1998;16:1713-21.
51. Fan S, Wang J, Yuan R, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999;284:1354-6.
52. Wang C, Fan S, Li Z, et al. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor α activity. Cancer Res 2005;65:6557-67.
53. Vaziri SA, Tubbs RR, Darlington G, Casey G. Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mot Pathol 2001;54:259-63.
54. Osin P, Gusterson BA, Philp E, et al. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 1998;34:1683-6.
55. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286:2251-6.
56. Cable PL, Wilson CA, Calzone FJ, et al. Novel consensus DNA-binding sequence for BRCA1 protein complexes. Mol Carcinog 2003;38: 85-96.
57. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet 1998; 19:254-6.
58. Yarden RI, Brody LC. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci U S A 1999;96: 4983-8.
59. Bochar DA, Wang L, Beniya H, et al. BRCA1 is associated with a human SWI/ SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000;102:257-65.
60. Pao GM, Janknecht R., Ruffner H, Hunter T, Verma IM. CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci U S A 2000;97:1020-5.
61. Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 2002;86:41-65.
62. Stimson L, Rowlands MG, Newbatt YM, et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 2005;4:1521-32.
63. Richon VM, O'Brien JP. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 2002; 8:662-4.
64. Williamson EA, Dadmanesh F, Koeffler HP. BRCA1 transactivates the cyclin-dependent kinase inhibitor p27(Kip1). Oncogene 2002;21: 3199-206.
65. Thangaraju M, Kaufmann SH, Couch FJ. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 2000;275:33487-96.
66. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221-8.
67. Freneaux P, Stoppa-Lyonnet D, Mouret E, et al. Low expression of bcl-2 in Brca1 -associated breast cancers. Br J Cancer 2000;83:1318-22.
68. Venkitaraman AR. Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat Rev Cancer 2004;4:266-76.
69. Sowter HM, Ashworth A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis 2005;26:1651-6.
70. Tutt ANJ, Lord CJ, McCabe N, Farmer H, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005;70:1-10.
71. Schnell JD, Hicke L. Non-traditional functions of ubiquitin and ubiquitin-binding proteins. J Biol Chem 2003;278:35857-60.
72. Xia Y, Pao GM, Chen HW, Verma IM, Hunter T. Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J Biol Chem 2003;278:5255-63.
73. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci U S A 2001;98:5134-9.
74. Chen A, Kleiman FE, Manley JL, Ouchi T, Pan ZQ. Autoubiquitination of the BRCA1 *BARD1 RING ubiquitin ligase. J Biol Chem 2002;277: 22085-92.
75. Sato K, Hayami R, Wu W, et al. Nucleophosmin/B23 is a candidate substrate for the BRCA1-1 ubiquitin ligase. J Biol Chem 2004;279: 30919-22.
76. Starita LM, Machida Y, Sankaran S, et al. BRCA1-dependent ubiquitination of γ-tubulin regulates centrosome number. Mol Cell Biol 2004; 24:8457-66.
77. Ogawara Y, Kishishita S, Obata T, et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002;277: 21843-50.
78. Jensen DE, Proctor M, Marquis ST, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16:1097-112.